JP2004500801A5 - - Google Patents

Download PDF

Info

Publication number
JP2004500801A5
JP2004500801A5 JP2000547235A JP2000547235A JP2004500801A5 JP 2004500801 A5 JP2004500801 A5 JP 2004500801A5 JP 2000547235 A JP2000547235 A JP 2000547235A JP 2000547235 A JP2000547235 A JP 2000547235A JP 2004500801 A5 JP2004500801 A5 JP 2004500801A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
orf
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000547235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500801A (ja
JP5102414B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/009346 external-priority patent/WO1999057280A2/en
Publication of JP2004500801A publication Critical patent/JP2004500801A/ja
Publication of JP2004500801A5 publication Critical patent/JP2004500801A5/ja
Application granted granted Critical
Publication of JP5102414B2 publication Critical patent/JP5102414B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2000547235A 1998-05-01 1999-04-30 髄膜炎菌抗原および組成物 Expired - Fee Related JP5102414B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US8375898P 1998-05-01 1998-05-01
US60/083,758 1998-05-01
US9486998P 1998-07-31 1998-07-31
US60/094,869 1998-07-31
US9899498P 1998-09-02 1998-09-02
US9906298P 1998-09-02 1998-09-02
US60/099,062 1998-09-02
US60/098,994 1998-09-02
US10379698P 1998-10-09 1998-10-09
US10374998P 1998-10-09 1998-10-09
US10379498P 1998-10-09 1998-10-09
US60/103,794 1998-10-09
US60/103,749 1998-10-09
US60/103,796 1998-10-09
US12152899P 1999-02-25 1999-02-25
US60/121,528 1999-02-25
PCT/US1999/009346 WO1999057280A2 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009125889A Division JP2009183306A (ja) 1998-05-01 2009-05-25 髄膜炎菌抗原および組成物
JP2010031866A Division JP2010166916A (ja) 1998-05-01 2010-02-16 髄膜炎菌抗原および組成物

Publications (3)

Publication Number Publication Date
JP2004500801A JP2004500801A (ja) 2004-01-15
JP2004500801A5 true JP2004500801A5 (enExample) 2010-04-08
JP5102414B2 JP5102414B2 (ja) 2012-12-19

Family

ID=27574612

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2000547235A Expired - Fee Related JP5102414B2 (ja) 1998-05-01 1999-04-30 髄膜炎菌抗原および組成物
JP2009125889A Withdrawn JP2009183306A (ja) 1998-05-01 2009-05-25 髄膜炎菌抗原および組成物
JP2010031866A Withdrawn JP2010166916A (ja) 1998-05-01 2010-02-16 髄膜炎菌抗原および組成物
JP2012140207A Pending JP2012191945A (ja) 1998-05-01 2012-06-21 髄膜炎菌抗原および組成物
JP2012140208A Withdrawn JP2012191946A (ja) 1998-05-01 2012-06-21 髄膜炎菌抗原および組成物
JP2013157835A Expired - Lifetime JP6025675B2 (ja) 1998-05-01 2013-07-30 髄膜炎菌抗原および組成物
JP2013157834A Expired - Lifetime JP6025674B2 (ja) 1998-05-01 2013-07-30 髄膜炎菌抗原および組成物
JP2016154472A Withdrawn JP2016222709A (ja) 1998-05-01 2016-08-05 髄膜炎菌抗原および組成物
JP2016192774A Withdrawn JP2017012195A (ja) 1998-05-01 2016-09-30 髄膜炎菌抗原および組成物

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2009125889A Withdrawn JP2009183306A (ja) 1998-05-01 2009-05-25 髄膜炎菌抗原および組成物
JP2010031866A Withdrawn JP2010166916A (ja) 1998-05-01 2010-02-16 髄膜炎菌抗原および組成物
JP2012140207A Pending JP2012191945A (ja) 1998-05-01 2012-06-21 髄膜炎菌抗原および組成物
JP2012140208A Withdrawn JP2012191946A (ja) 1998-05-01 2012-06-21 髄膜炎菌抗原および組成物
JP2013157835A Expired - Lifetime JP6025675B2 (ja) 1998-05-01 2013-07-30 髄膜炎菌抗原および組成物
JP2013157834A Expired - Lifetime JP6025674B2 (ja) 1998-05-01 2013-07-30 髄膜炎菌抗原および組成物
JP2016154472A Withdrawn JP2016222709A (ja) 1998-05-01 2016-08-05 髄膜炎菌抗原および組成物
JP2016192774A Withdrawn JP2017012195A (ja) 1998-05-01 2016-09-30 髄膜炎菌抗原および組成物

Country Status (16)

Country Link
US (9) US7576176B1 (enExample)
EP (23) EP2261353A3 (enExample)
JP (9) JP5102414B2 (enExample)
CN (3) CN100379757C (enExample)
AT (2) ATE388230T1 (enExample)
AU (1) AU761780B2 (enExample)
BR (1) BR9910089A (enExample)
CA (2) CA2330838C (enExample)
CY (2) CY1109649T1 (enExample)
DE (2) DE69938302T2 (enExample)
DK (2) DK1093517T3 (enExample)
ES (3) ES2294629T3 (enExample)
MX (4) MX339406B (enExample)
NZ (4) NZ541361A (enExample)
PT (3) PT1944371E (enExample)
WO (1) WO1999057280A2 (enExample)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP1029052B1 (en) * 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
EP1137777B1 (en) * 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Novel compounds derived from neisseria meningitidis
CN1350585A (zh) * 1999-01-15 2002-05-22 史密丝克莱恩比彻姆生物有限公司 脑膜炎奈瑟氏菌多肽basb052
EP1144643A1 (en) 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigen
AU2292800A (en) * 1999-01-22 2000-08-07 Smithkline Beecham Biologicals (Sa) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides andprotective antibodies
AU2109700A (en) 1999-01-22 2000-08-07 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
GB9902937D0 (en) * 1999-02-10 1999-03-31 Smithkline Beecham Biolog Novel compounds
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
PT1163343E (pt) 1999-03-12 2010-02-23 Glaxosmithkline Biolog Sa Polipéptidos antigénicos de neisseria meningitidis, polinucleótidos e anticorpos protectores correspondentes
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
AU2013200678B2 (en) * 1999-05-19 2014-08-21 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
AU2003270970B2 (en) * 1999-08-03 2005-05-26 Smithkline Beecham Biologicals S.A. Vaccine composition
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
RU2322451C2 (ru) * 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2012202488B2 (en) * 2001-09-06 2014-01-16 Glaxosmithkline Biologicals S.A. Hybrid and tandem expression of Neisserial proteins
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2462646C (en) * 2001-10-03 2013-02-12 Chiron Corporation Adjuvanted meningococcus compositions
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) * 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP1654283B1 (en) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
ATE395356T1 (de) * 2004-06-29 2008-05-15 Ct For Disease Control Dept Of Oberflächenprotein aus neisserien
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419918D0 (en) * 2004-09-08 2004-10-13 Imp College Innovations Ltd Vaccine
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP1723964A1 (en) * 2005-05-20 2006-11-22 Institut Pasteur Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1962902A2 (en) * 2005-12-06 2008-09-03 Universita Degli Studi di Padova Methods and compositions relating to adhesins as adjuvants
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EA018068B1 (ru) 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP2297578A2 (en) * 2008-05-19 2011-03-23 Novartis AG Vaccine assays
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
GB0810742D0 (en) * 2008-06-12 2008-07-16 Univ Nottingham Enzyme
AU2009288095A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
CN102482327B (zh) 2009-06-22 2014-10-29 财团法人卫生研究院 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
MX345967B (es) 2009-10-30 2017-02-28 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
US9365624B2 (en) 2010-03-11 2016-06-14 Glaxosmithkline Biologicals, S.A. Vaccine
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
EP3242135B1 (en) 2010-04-08 2020-07-01 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
US20120070457A1 (en) * 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
PL2491788T3 (pl) 2011-02-25 2016-07-29 Kraft Foods R & D Inc Wyrób spożywczy z formowanym korpusem
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
BR112014004606A2 (pt) 2011-08-31 2017-03-21 Children's Hospital & Res Center Oakland sequências modificadas geneticamente para facilitar a expressão de antígenos em neisseria e métodos de uso
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
BR112014019166A2 (pt) 2012-02-02 2017-07-04 Novartis Ag promotores para expressão aumentada de proteína em meningococos
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
US9902756B2 (en) 2012-11-16 2018-02-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
BR112016002150A2 (pt) 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3838918B1 (en) * 2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
CN108950056B (zh) * 2018-08-30 2021-08-20 安徽农业大学 与小麦种子休眠/穗发芽抗性相关的caps标记及其检测方法
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
MX2021010160A (es) * 2019-02-22 2021-09-14 Evelo Biosciences Inc Preparaciones de membrana bacteriana.
GB2583070B (en) 2019-03-20 2023-09-13 Schlumberger Technology Bv Viscosification of aqueous solutions
US20230041432A1 (en) * 2019-03-21 2023-02-09 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
EP4007600A4 (en) * 2019-08-01 2023-08-23 Trustees of Tufts College VACCINE COMPOSITIONS AND ANTIGEN SELECTION METHODS
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20220152402A (ko) * 2019-11-25 2022-11-15 그리피스 유니버시티 임균 감염에 대한 면역원성 단백질
US11865981B2 (en) * 2020-05-05 2024-01-09 Thor Tech, Inc. Wire loom support
EP4240843A1 (en) 2020-11-04 2023-09-13 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
CN113773366B (zh) * 2021-07-27 2023-06-16 四川丽妍工坊生物科技有限公司 一种抗炎多肽bmp14及其制备方法和应用
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
CN119020251A (zh) * 2024-08-26 2024-11-26 南昌大学 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR75411B (enExample) 1981-04-29 1984-07-16 Biogen Nv
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
FI871919A7 (fi) 1986-05-02 1987-11-03 Gist Brocades Nv Erityssignaaliselektiovektoreita solunulkoiseen proteiinisynteesiin Bacillus-bakteereilla
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
ATE247708T1 (de) 1986-10-02 2003-09-15 Massachusetts Inst Technology Verfahren zur regulierung der metabolischen stabilität von proteinen
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE3888561T2 (de) 1987-03-23 1994-09-01 Zymogenetics Inc Hohe Proteinsyntheserate in Hefe.
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
EP0318216B2 (en) 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
HU218717B (hu) 1989-03-17 2000-11-28 E. I. Du Pont De Nemours And Co. Nukleinsav-termelést fokozó növényi eredetű génfragmentek és eljárás előállításukra
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DE4091460C2 (de) 1989-08-15 1996-05-09 Pasminco Australia Ltd Absorption von Zinkdampf in geschmolzenem Blei
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
RU2142467C1 (ru) 1990-07-27 1999-12-10 Чирон Диагностикс Корпорейшн Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты
ATE253114T1 (de) * 1990-08-23 2003-11-15 Univ North Carolina Transferrin bindende proteine aus neisseria- gonorrhoeae und neisseria-meningitidis
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
ES2144414T3 (es) 1990-12-20 2000-06-16 Arch Dev Corp The University O Control de la expresion de un gen por medio de una radiacion ionizante.
AU1411492A (en) * 1991-01-31 1992-09-07 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
CA2105382C (en) 1991-03-14 1999-01-19 Neil Goldstein Recombinant hybrid porin epitopes
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH0515375A (ja) * 1991-07-11 1993-01-26 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
WO1993025685A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Cloning and characterization of the cell death genes ced-3 and ced-4
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
GB9216851D0 (en) 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
CA2145535C (en) 1992-09-25 2007-07-17 Axel Kahn Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
WO1994008013A1 (en) * 1992-10-07 1994-04-14 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Pilin variants and uses thereof
AU694097B2 (en) 1992-11-18 1998-07-16 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
WO1994028157A1 (en) 1993-05-26 1994-12-08 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
JPH09505561A (ja) 1993-10-01 1997-06-03 アメリカ合衆国 神経系の遺伝子治療
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0710118B1 (en) 1994-04-20 1998-11-25 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2722210B1 (fr) * 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
CA2218741A1 (en) 1995-04-21 1996-10-24 Johns Hopkins University Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
JPH11505128A (ja) 1995-05-22 1999-05-18 カイロン コーポレイション キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
SK165197A3 (en) * 1995-06-07 1999-01-11 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6172192B1 (en) * 1996-01-26 2001-01-09 Innogenetics N.V. Toxoplasma gondii antigen Tg20
JP2001508758A (ja) 1996-02-01 2001-07-03 ノース・アメリカン・バクシーン・インコーポレイテッド グループｂナイセリア・メニンギチジス外膜（ｍｂ３）タンパク質の酵母からの発現およびワクチン
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
CN1220703A (zh) * 1996-03-29 1999-06-23 阿斯特拉公司 与幽门螺杆菌及其疫备组合物有关的核酸和氨基酸序列
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのｂｐｉタンパク質産物の治療用途
US6096529A (en) * 1996-06-10 2000-08-01 National Research Council Of Canada Recombinant α-2,3-sialyltransferases and their uses
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
EP0818465A1 (en) 1996-07-12 1998-01-14 Institute of Molecular Biotechnology (IMB) Department of Genome Analysis Genomic sequence of Rhizobium sp. NGR234 symbiotic plasmid
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
ATE497004T1 (de) * 1996-12-20 2011-02-15 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
US5763589A (en) * 1997-01-09 1998-06-09 Incyte Pharmaceuticals, Inc. Human membrane protein
EP1029052B1 (en) * 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
US6214566B1 (en) * 1998-11-16 2001-04-10 The Administrators Of The Tulane Educational Fund Method for detecting anti-squalene antibodies
EP1137777B1 (en) * 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Novel compounds derived from neisseria meningitidis
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
PT1163343E (pt) * 1999-03-12 2010-02-23 Glaxosmithkline Biolog Sa Polipéptidos antigénicos de neisseria meningitidis, polinucleótidos e anticorpos protectores correspondentes
ES2522667T3 (es) * 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
KR20060019515A (ko) 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2656474A1 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
AU2009288095A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
WO2010065473A2 (en) 2008-12-01 2010-06-10 Applied Materials, Inc. Gas distribution blocker apparatus
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo

Similar Documents

Publication Publication Date Title
JP2004500801A5 (enExample)
Hanson et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection
Pruksakorn et al. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies
JP2013047274A (ja) Ｎｅｉｓｓｅｒｉａ配合組成物
EA001789B1 (ru) Выделенные, по существу очищенные, поверхностные антигены белковой природы neisseria meningitidis и neisseria gonorrhoeae, их фрагменты и последовательности днк
NZ520445A (en) Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
NZ505374A (en) Isolated fragment of surface protein of N. meningitidis and compositions thereof for treating or diagnosing Meningococcal meningitis and septicemia
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
JPH04504719A (ja) 合成緑膿菌線毛ペプチド及び関連するワクチン及び診断剤
Ye et al. Molecular characterization of a gene encoding a membrane protein of Spiroplasma citri
CA2387392A1 (en) Polypeptide fragments comprising c-terminal portion of helicobacter catalase
WO2019018744A1 (en) IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
WO2024076960A2 (en) Novel chimeric multi-protein based recombinant vaccine antigens for prevention of lyme disease in animals and humans
CN111344007A (zh) 抗a组链球菌的免疫原性肽
MX2008012664A (es) Composicion farmaceutica que comprende la proteina nmb0938.
MX2008012665A (es) Composicion farmaceutica que comprende la proteina nmb0606.
RU2335505C2 (ru) Белок nmb0928 и его применение в фармацевтических композициях
CN112449603A (zh) 链球菌中毒性休克综合征
CN101116744B (zh) 组合式奈瑟球菌组合物
RU2773464C1 (ru) Модифицированный белок, связывающий фактор н
AU772513B2 (en) Polypeptide fragments comprising C-terminal portion of helicobacter catalase
EP1977761A2 (en) Pharmaceutical compositions containing protein nma0939
JP2013541322A (ja) 組換え髄膜炎菌（ナイセリア・メニンギティディス）ＰｏｒＡポーリンタンパク質
Ogun et al. The oligomerization domain of C4-binding protein acts as an adjuvant: a fusion protein of MSP119 with the murine C4bp domain protects mice against malaria.
Garman et al. MHC Class II and Non-MHC Class II Genes Differentially Influence Humoral Immunity to Bacillus anthracis Lethal Factor...